|
Novel therapeutic choices in immune aplastic anemia |
Sep 2020 |
F1000Research |
Aplastic Anemia |
|
Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria. |
Sep 2020 |
PloS One |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
The IPSS-R more accurately captures fatigue severity of newly diagnosed patients with myelodysplastic syndromes compared with the IPSS index |
Sep 2020 |
Leukemia |
Myelodysplastic Syndromes (MDS) |
|
Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience |
Sep 2020 |
Leukemia & Lymphoma |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
|
The Problem of TP53-Mutant MDS/AML |
Sep 2020 |
Clinical Lymphoma , Myeloma & Leukemia |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
|
New Approaches for Anemia in MDS |
Sep 2020 |
Clinical Lymphoma , Myeloma & Leukemia |
Myelodysplastic Syndromes (MDS) |
|
Pitfalls in Assessing Response to Treatment in MDS |
Sep 2020 |
Clinical Lymphoma , Myeloma & Leukemia |
Myelodysplastic Syndromes (MDS) |
|
Content validity of patient-reported outcomes for use in lower-risk myelodysplastic syndromes |
Aug 2020 |
Journal of Patient-Reported Outcomes |
Myelodysplastic Syndromes (MDS) |
|
Guideline-based indicators for adult patients with myelodysplastic syndromes |
Aug 2020 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
|
Diagnosis and treatment of pediatric myelodysplastic syndromes: A survey of the North American Pediatric Aplastic Anemia Consortium |
Aug 2020 |
Pediatric Blood & Cancer |
Aplastic Anemia, Myelodysplastic Syndromes (MDS), Pediatric |
